Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain
Gregory N. Ruegsegger, Patrick M. Vanderboom, Surendra Dasari, Katherine A. Klaus, Parijat Kabiraj, Christina B. McCarthy, Claudia F. Lucchinetti, K. Sreekumaran Nair
Gregory N. Ruegsegger, Patrick M. Vanderboom, Surendra Dasari, Katherine A. Klaus, Parijat Kabiraj, Christina B. McCarthy, Claudia F. Lucchinetti, K. Sreekumaran Nair
View: Text | PDF
Research Article Endocrinology Metabolism

Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain

  • Text
  • PDF
Abstract

Insulin resistance associates with increased risk for cognitive decline and dementia; however, the underpinning mechanisms for this increased risk remain to be fully defined. As insulin resistance impairs mitochondrial oxidative metabolism and increases ROS in skeletal muscle, we considered whether similar events occur in the brain, which — like muscle — is rich in insulin receptors and mitochondria. We show that high-fat diet–induced (HFD-induced) brain insulin resistance in mice decreased mitochondrial ATP production rate and oxidative enzyme activities in brain regions rich in insulin receptors. HFD increased ROS emission and reduced antioxidant enzyme activities, with the concurrent accumulation of oxidatively damaged mitochondrial proteins and increased mitochondrial fission. Improvement of insulin sensitivity by both aerobic exercise and metformin ameliorated HFD-induced abnormalities. Moreover, insulin-induced enhancement of ATP production in primary cortical neurons and astrocytes was counteracted by the insulin receptor antagonist S961, demonstrating a direct effect of insulin resistance on brain mitochondria. Further, intranasal S961 administration prevented exercise-induced improvements in ATP production and ROS emission during HFD, supporting that exercise enhances brain mitochondrial function by improving insulin action. These results support that insulin sensitizing by exercise and metformin restores brain mitochondrial function in insulin-resistant states.

Authors

Gregory N. Ruegsegger, Patrick M. Vanderboom, Surendra Dasari, Katherine A. Klaus, Parijat Kabiraj, Christina B. McCarthy, Claudia F. Lucchinetti, K. Sreekumaran Nair

×

Figure 4

Intranasal insulin receptor antagonism impairs mitochondrial function.

Options: View larger image (or click on image) Download as PowerPoint
Intranasal insulin receptor antagonism impairs mitochondrial function.
(...
(A) Intranasal injection of the insulin receptor antagonist S961 (1 μg) completely blocks, and further lowers, AKT and GSK3-β phosphorylation in the hippocampus 2 hours after injection of intranasal insulin (2 IU) (n = 3). (B and C) Daily intranasal injection of S961 for 7 days decreased citrate synthase (CS) (B) and cytochrome c oxidase (COX) (C) activities in the hippocampus (n = 8). (D) S961 decreased mitochondrial ATP production rate (MAPR) in isolated cerebral mitochondria (n = 8). (E) S961increased ROS emission in isolated cerebral mitochondria (n = 8). (F) S961 increased phosphorylation of DRP1 and Ser-616 in the hippocampus (n = 6). (G and H) S961 completely attenuated increased MAPR (G) and decreased ROS emission (H) in primary neurons, astrocytes, and mixed-glial cultures following 18-hour treatment with insulin (100 nM) or insulin plus S961 (n = 4). Data represent means ± SEM and were analyzed with 2-tailed Student’s t test (B–F) or 1-way ANOVA followed by Tukey’s multiple comparisons post hoc test (A, G, and H); *P < 0.05; **P < 0.01; ***P <0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts